PubMed Health⌕ Search

Biomedical subjects

D Micic

Publications and source records attributed to D Micic.

42 records · Page 3Linked to original sources
PubMedDate not supplied

Regulation of growth hormone secretion by the growth hormone releasing hexapeptide (GHRP-6).

Growth hormone (GH) secretion is regulated by a complex system of central and peripheral signals. Recently, a new GH-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) called GHRP-6 which specifically releases GH has been studied. In the present work the mechanism of action of GHRP-6 has been addressed in experimental animal models as well as in obese subjects. GHRP-6 releases GH independently of the hypothalamic factors GHRH and somatostatin and is a powerful GH releaser in obesity.

Animals↗
PubMedDate not supplied

[Effect of cilazapril on insulin sensitivity in patients with essential arterial hypertension].

Insulin resistance is defined as a state with decreased insulin utilisation in peripheral tissues, despite of different plasma insulin values. Insulin resistance is one of the postulated pathophysiological mechanisms that participates in the development of essential hypertension. Hyperinsulinaemia is considered as a compensatory feature of insulin resistance. There way be a few possible mechanisms by which hyperinsulinaemia affects blood pressure. Another possibility is that insulin resistance per se, by some uncertain mechanisms, causes essential hypertension [1, 5]. We evaluated insulin sensitivity in 24 patients with mild-to-moderate essential hypertension before and after cilazapril monotherapy during 12 weeks. Insulin sensitivity (Si) was assessed by minimal model test (MINMOD) using frequently sampled intravenous glucose tolerance test in 0 week and after 12 weeks of treatment. After a 12-week cilazapril treatment insulin sensitivity significantly increased, while glucose efficacy was relatively unchanged.

Adult↗
PubMedDate not supplied

Effect of 12 months of recombinant human growth hormone replacement therapy on insulin sensitivity in GH-deficient adults as determined by different methods.

BACKGROUND: Controversial results have been obtained in measuring insulin sensitivity (S(I)) during recombinant human growth hormone (rhGH) treatment in adult growth hormone deficient (GH-deficient) patients. AIMS: The aim of our study was to estimate S(I) before and during treatment using three different methods for quantifying insulin sensitivity in GH-deficient adults treated with rhGH. SETTINGS AND DESIGN: Twenty-one GH-deficient adults were treated with rhGH during 12 months. S(I) was estimated using Minimal model analysis, Homeostatic Model of Assessment (HOMA) and Quantitative Insulin Sensitivity Check Index (QUICKI) before and after 3, 6, 9 and 12 months of rhGH therapy. MATERIAL AND METHODS: Oral Glucose Tolerance Test (OGTT) and Frequently Sampled Intravenous Glucose Tolerance Test (FSIGT) were performed in each patient at respective time intervals. QUICKI and HOMA were calculated using basal values of glucose and insulin from FSIGT. Minimal model computer analysis was calculated from glucose and insulin data obtained during FSIGT. STATISTICAL ANALYSIS: Area under the curve for glucose, insulin and C-peptide were calculated using trapezoidal rule from OGTT data. Differences and correlations were tested using ANOVA for repeated measures, Wilcoxon's matched-paired test, paired t-test, Pearson's correlation and Bland Altman plot. RESULTS: There were no significant changes in S(I) using Minimal model analysis and QUICKI during rhGH treatment. On the contrary, HOMA analysis indicated significant deterioration in S(I) after 12 months of therapy. CONCLUSION: Our study did not demonstrate any changes in S(I) using Minimal model and QUICKI analysis, while there was significant increase in insulin resistance using HOMA model. We suggest that the choice of method for the determination of S(I) may influence the interpretation of results concerning the effect of rhGH therapy on S(I) in GH-deficient adults.

Adult↗